Company Overview of PCI Biotech AS
PCI Biotech AS operates as a cancer-focused biopharmaceutical company in Norway. The company focuses on developing therapeutic products based on its proprietary photochemical internalization (PCI) technology in the areas of head and neck cancer, bile duct cancer, vaccination, and macromolecules. It is also developing PCI as a cytotoxic T ymphocyte (CTL) induction technology for therapeutic and prophylactic vaccination. The company was founded in 2000 and is based in Lysaker, Norway. As of June 16, 2008 PCI Biotech AS operates as a subsidiary of PCI Biotech Holding ASA.
Founded in 2000
47 67 11 54 00
47 67 11 54 01
Key Executives for PCI Biotech AS
PCI Biotech AS Key Developments
Similar Private Companies By Industry
|Arctic Nutrition AS||Europe|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|NYC2012, Inc.||United States|
|Tax Management Inc||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact PCI Biotech AS, please visit pcibiotech.no. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.